Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + metoclopramide is a fixed-dose oral combination medication used primarily for the treatment of migraine attacks. Paracetamol acts as an analgesic and antipyretic, providing pain relief by inhibiting prostaglandin synthesis in the central nervous system. Metoclopramide is a dopamine D2 receptor antagonist with antiemetic and prokinetic properties; it alleviates nausea and vomiting associated with migraines by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, antagonizing serotonin 5-HT3 receptors, agonizing serotonin 5-HT4 receptors, and enhancing gastric motility. The combination not only relieves headache but also addresses delayed gastric emptying often seen during migraine attacks, potentially improving absorption of paracetamol[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + metoclopramide.